SCHEMBL2175891

SCHEMBL2175891

CNc1nccc(-c2cc(NC(=O)c3ccc(OC)cc3)c3cc(OC)ccc3c2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.49
NCOR1 O75376 1/20 0.49
HDAC2 Q92769 1/20 0.49
PIK3CA P42336 2/20 0.49
SRC P12931 1/20 0.47
FLT3 P36888 1/20 0.47
ITK Q08881 1/20 0.47
F10 P00742 2/20 0.46
KMT2A Q03164 3/20 0.45
TP53 P04637 2/20 0.45
GAA P10253 1/20 0.45
MAPT P10636 4/20 0.44
ADORA3 P0DMS8 3/20 0.44
KDM4E B2RXH2 3/20 0.44
MEN1 O00255 1/20 0.44
RECQL P46063 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
ALDH1A1 P00352 1/20 0.43
HPGD P15428 1/20 0.43
HDAC1 Q13547 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2178971 0.94 HDAC2 (0.48) HDAC3NCOR1HDAC2PIK3CASRC
SCHEMBL2178371 0.93 BTK (0.46) HDAC3NCOR1HDAC2PIK3CASRC
SCHEMBL2175910 0.93 TDO2 (0.46) HDAC3NCOR1HDAC2PIK3CASRC
SCHEMBL2178148 0.89 HSD17B1 (0.46) HDAC3NCOR1HDAC2PIK3CASMN1; SMN2
SCHEMBL6128772 0.86 NPC1 (0.44) HDAC3NCOR1HDAC2PIK3CAADORA3
SCHEMBL2178808 0.86 CASP2 (0.41) HDAC3NCOR1HDAC2PIK3CAPIK3CB
SCHEMBL6128802 0.85 HDAC3 (0.43) HDAC3NCOR1HDAC2PIK3CATP53
SCHEMBL2178751 0.84 AAK1 (0.42) HDAC3NCOR1HDAC2PIK3CAFLT3
SCHEMBL2176307 0.83 KDR (0.41) HDAC3NCOR1HDAC2PIK3CAKMT2A
SCHEMBL6128782 0.82 HDAC3 (0.38) HDAC3NCOR1HDAC2PIK3CASRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173808-B2 Substituted naphthalenyl-pyrimidine compounds ARQULE, INC. (US) 2012-05-08 US claimed
EP-2519519-A2 SUBSTITUTED NAPHTHALENYL-PYRIMIDINE COMPOUNDS ArQule, Inc. (US) 2012-11-07 EP disclosed
US-8173808-B2 Substituted naphthalenyl-pyrimidine compounds ARQULE, INC. (US) 2012-05-08 US disclosed
US-8173808-B2 Substituted naphthalenyl-pyrimidine compounds ARQULE, INC. (US) 2012-05-08 US disclosed
WO-2011082268-A2 SUBSTITUTED NAPHTHALENYL-PYRIMIDINE COMPOUNDS ARQULE INC. (US) 2011-07-07 WO disclosed
US-20110166137-A1 Substituted Naphthalenyl-Pyrimidine Compounds ARQULE, INC. (US) 2011-07-07 US disclosed
US-20110166137-A1 Substituted Naphthalenyl-Pyrimidine Compounds ARQULE, INC. (US) 2011-07-07 US disclosed
WO-2011082268-A2 SUBSTITUTED NAPHTHALENYL-PYRIMIDINE COMPOUNDS ARQULE INC. (US) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166137-A1 Substituted Naphthalenyl-Pyrimidine Compounds DPYD, TP53, TYMP HDAC3 1641/4885NCOR1 418/4885HDAC2 2152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.